Abstract
The prevalence of resistant arterial hypertension (RH) is approximately 10-12%. Ambulatory Blood Pressure Monitoring is highly recommended in these patients to define true and white-coat RH since the latter group has a better prognosis. If well tolerated, a triple therapy plan including a diuretic, an ACE inhibitor or an angiotensin receptor blocker, and a calcium channel blocker is recommended. Regarding second-line drugs, most evidence has focused on the use of aldosterone antagonists. Data from short-term studies have suggested that percutaneous renal sympathetic denervation is a safe and effective therapeutic option in carefully selected patients with RH. However, long-term studies with large patient populations that evaluate the appearance of cardiovascular events are needed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
